Abstract |
Yellow Fever (YF) and Lassa Fever (LF) are two prevalent hemorrhagic fevers co-circulating in West Africa and responsible for thousands of deaths annually. The YF vaccine 17D has been used as a vector for the Lassa virus glycoprotein precursor (LASV-GPC) or their subunits, GP1 (attachment glycoprotein) and GP2 (fusion glycoprotein). Cloning shorter inserts, LASV-GP1 and -GP2, between YF17D E and NS1 genes enhanced genetic stability of recombinant viruses, YF17D/LASV-GP1 and -GP2, in comparison with YF17D/LASV-GPC recombinant. The recombinant viruses were replication competent and properly processed YF proteins and LASV GP antigens in infected cells. YF17D/LASV-GP1 and -GP2 induced specific CD8+ T cell responses in mice and protected strain 13 guinea pigs against fatal LF. Unlike immunization with live attenuated reassortant vaccine ML29, immunization with YF17D/LASV-GP1 and -GP2 did not provide sterilizing immunity. This study demonstrates the feasibility of YF17D-based vaccine to control LF in West Africa.
|
Authors | Xiaohong Jiang, Tim J Dalebout, Peter J Bredenbeek, Ricardo Carrion Jr, Kathleen Brasky, Jean Patterson, Marco Goicochea, Joseph Bryant, Maria S Salvato, Igor S Lukashevich |
Journal | Vaccine
(Vaccine)
Vol. 29
Issue 6
Pg. 1248-57
(Feb 01 2011)
ISSN: 1873-2518 [Electronic] Netherlands |
PMID | 21145373
(Publication Type: Journal Article, Research Support, N.I.H., Extramural)
|
Copyright | Copyright © 2010 Elsevier Ltd. All rights reserved. |
Chemical References |
- Drug Carriers
- Vaccines, Synthetic
- Viral Envelope Proteins
- Yellow Fever Vaccine
- glycoprotein gp1, lassa virus
- glycoprotein gp2, lassa virus
|
Topics |
- Animals
- CD8-Positive T-Lymphocytes
(immunology)
- Disease Models, Animal
- Drug Carriers
- Female
- Genetic Vectors
- Guinea Pigs
- Lassa Fever
(prevention & control)
- Mice
- Mice, Inbred CBA
- Vaccines, Synthetic
(genetics, immunology)
- Viral Envelope Proteins
(genetics, immunology)
- Yellow Fever Vaccine
(genetics, immunology)
|